Aldoxorubicin is Promising Lead Cancer Drug Candidate for CytRx Corp. (CYTR)

Los Angeles based CytRx is a biopharmaceutical research and development company specializing in oncology. The company has three key cancer treating drug candidates in various phases of development, with the primary candidate being aldoxorubicin, an improved version of the widely used chemotherapeutic agent doxorubicin. Tamibarotene, the second drug candidate, is an orally available synthetic retinoid compound for which CytRx holds the North American and European rights for the treatment of non-small-cell lung cancer and APL. Bafetinib, the other drug candidate, is under development for treatment of chronic lymphocytic leukemia.

Aldoxorubicin, the company’s main drug candidate, is a novel conjugate of doxorubicin, a commonly prescribed chemotherapeutic agent that binds to albumin, the most abundant protein in blood plasma, and is circulated throughout the body. Doxorubicin is used, either alone or in combination with other chemotherapy agents, as a treatment for a variety of cancers. The addition of aldoxorubicin is designed to essentially improve the release of doxorubicin in tumors, where it does the most good. This conjugate formulation has the potential to safely deliver greater amounts of doxorubicin directly to the tumor compared with standard doxorubicin treatment, which could lead to improved efficacy.

In a Phase 1 clinical trial, aldoxorubicin was administered in doses at up to six times the standard dosing of doxorubicin without an increase in observed side effects over those historically seen with doxorubicin. Additional tests have demonstrated statistically significant therapeutic results in breast, ovarian, pancreatic, and small cell lung cancers. Results of these studies were published in the peer-reviewed journal Investigational New Drugs. In tests for soft tissue sarcoma, median estimated progression-free survival for advanced soft tissue sarcoma patients in the trial was 6.4 months with a range of 1.0 to more than 10.7 months. This compares favorably with the historical median progression-free survival for this patient population of approximately 3 months.

CytRx holds the exclusive worldwide rights to aldoxorubicin.

For additional information, visit www.cytrx.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html